Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
December 05, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...